Terms: = Bone cancer AND ZNF198, Q9UBW7, SCLL, RAMP, MYM, FIM, 7750
43 results:
1. Balance of Gata3 and ramp2 in hepatocytes regulates hepatic vascular reconstitution in postoperative liver regeneration.
Wang B; Shen H; Wei Y; Liu F; Yang Y; Yu H; Fu J; Cui X; Yu T; Xu Y; Liu Y; Dong H; Shen F; Zhou W; Liu H; Chen Y; Wang H
J Hepatol; 2024 Feb; 80(2):309-321. PubMed ID: 37918568
[TBL] [Abstract] [Full Text] [Related]
2. Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia.
Allan JN; Flinn IW; Siddiqi T; Ghia P; Tam CS; Kipps TJ; Barr PM; Elinder Camburn A; Tedeschi A; Badoux XC; Jacobs R; Kuss BJ; Trentin L; Zhou C; Szoke A; Abbazio C; Wierda WG
Clin Cancer Res; 2023 Jul; 29(14):2593-2601. PubMed ID: 37282671
[TBL] [Abstract] [Full Text] [Related]
3. Determining Association between Lung cancer Mortality Worldwide and Risk Factors Using Fuzzy Inference Modeling and Random Forest Modeling.
Wu X; Denise BB; Zhan FB; Zhang J
Int J Environ Res Public Health; 2022 Oct; 19(21):. PubMed ID: 36361041
[TBL] [Abstract] [Full Text] [Related]
4. A truncated derivative of FGFR1 kinase cooperates with FLT3 and KIT to transform hematopoietic stem cells in syndromic and de novo AML.
Cai B; Liu Y; Chong Y; Mori SF; Matsunaga A; Zhang H; Fang X; Chang CS; Cowell JK; Hu T
Mol Cancer; 2022 Jul; 21(1):156. PubMed ID: 35906694
[TBL] [Abstract] [Full Text] [Related]
5. Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
Kater AP; Levin MD; Dubois J; Kersting S; Enggaard L; Veldhuis GJ; Mous R; Mellink CHM; van der Kevie-Kersemaekers AF; Dobber JA; Poulsen CB; Frederiksen H; Janssens A; Schjødt I; Dompeling EC; Ranti J; Brieghel C; Mattsson M; Bellido M; Tran HTT; Nasserinejad K; Niemann CU
Lancet Oncol; 2022 Jun; 23(6):818-828. PubMed ID: 35654052
[TBL] [Abstract] [Full Text] [Related]
6. Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.
Kersting S; Dubois J; Nasserinejad K; Dobber JA; Mellink C; van der Kevie-Kersemaekers AF; Evers LM; de Boer F; Koene HR; Schreurs J; van der Klift M; Velders GA; van der Spek E; van der Straaten HM; Hoogendoorn M; van Gelder M; Posthuma EFM; Visser HPJ; Houtenbos I; Idink CAM; Issa DE; Dompeling EC; van Zaanen HCT; Veelken H; Levenga H; Tick LW; Terpstra WE; Tonino SH; Boyer M; Mobasher M; Levin MD; Kater AP;
Lancet Haematol; 2022 Mar; 9(3):e190-e199. PubMed ID: 35240075
[TBL] [Abstract] [Full Text] [Related]
7. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
Tam CS; Allan JN; Siddiqi T; Kipps TJ; Jacobs R; Opat S; Barr PM; Tedeschi A; Trentin L; Bannerji R; Jackson S; Kuss BJ; Moreno C; Szafer-Glusman E; Russell K; Zhou C; Ninomoto J; Dean JP; Wierda WG; Ghia P
Blood; 2022 Jun; 139(22):3278-3289. PubMed ID: 35196370
[TBL] [Abstract] [Full Text] [Related]
8. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.
Soumerai JD; Mato AR; Dogan A; Seshan VE; Joffe E; Flaherty K; Carter J; Hochberg E; Barnes JA; Hamilton AM; Abramson JS; Batlevi CL; Matasar MJ; Noy A; Owens CN; Palomba ML; Kumar A; Takvorian T; Ni A; Choma M; Friedman C; Chadha P; Simkins E; Ruiters J; Sechio S; Portman D; Ramos L; Nolet N; Mahajan N; Martignetti R; Mi J; Scorsune K; Lynch J; McGree B; Hughes S; Grieve C; Roeker LE; Thompson M; Johnson PC; Roshal M; Huang J; Biondo J; Wu Q; Jacob A; Abdel-Wahab O; Zelenetz AD
Lancet Haematol; 2021 Dec; 8(12):e879-e890. PubMed ID: 34826411
[TBL] [Abstract] [Full Text] [Related]
9. Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
Davids MS; Rogers KA; Tyekucheva S; Wang Z; Pazienza S; Renner SK; Montegaard J; Ihuoma U; Lehmberg TZ; Parry EM; Wu CJ; Jacobson CA; Fisher DC; Thompson PA; Brown JR
Blood; 2022 Feb; 139(5):686-689. PubMed ID: 34788401
[TBL] [Abstract] [Full Text] [Related]
10. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.
Davids MS; Lampson BL; Tyekucheva S; Wang Z; Lowney JC; Pazienza S; Montegaard J; Patterson V; Weinstock M; Crombie JL; Ng SY; Kim AI; Jacobson CA; LaCasce AS; Armand P; Arnason JE; Fisher DC; Brown JR
Lancet Oncol; 2021 Oct; 22(10):1391-1402. PubMed ID: 34534514
[TBL] [Abstract] [Full Text] [Related]
11. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
Jain N; Keating M; Thompson P; Ferrajoli A; Burger JA; Borthakur G; Takahashi K; Estrov Z; Sasaki K; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang SA; Garg N; Wang X; Wei C; Cruz N; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda WG
JAMA Oncol; 2021 Aug; 7(8):1213-1219. PubMed ID: 34110383
[TBL] [Abstract] [Full Text] [Related]
12. Determination of Normal Values of the Basal Angle in the Era of Magnetic Resonance Imaging.
Ferreira JA; Botelho RV
World Neurosurg; 2019 Dec; 132():363-367. PubMed ID: 31541760
[TBL] [Abstract] [Full Text] [Related]
13. Coexisting of bone marrow fibrosis, dysplasia and an X chromosomal abnormality in chronic neutrophilic leukemia with CSF3R mutation: a case report and literature review.
Wu XB; Wu WW; Zhou Y; Wang X; Li J; Yu Y
BMC Cancer; 2018 Mar; 18(1):343. PubMed ID: 29587671
[TBL] [Abstract] [Full Text] [Related]
14. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.
Coutre S; Choi M; Furman RR; Eradat H; Heffner L; Jones JA; Chyla B; Zhou L; Agarwal S; Waskiewicz T; Verdugo M; Humerickhouse RA; Potluri J; Wierda WG; Davids MS
Blood; 2018 Apr; 131(15):1704-1711. PubMed ID: 29305552
[TBL] [Abstract] [Full Text] [Related]
15. Characterization of cancer Patients in Inpatient Rehabilitation Facilities: A Retrospective Cohort Study.
Mix JM; Granger CV; LaMonte MJ; Niewczyk P; DiVita MA; Goldstein R; Yates JW; Freudenheim JL
Arch Phys Med Rehabil; 2017 May; 98(5):971-980. PubMed ID: 28161317
[TBL] [Abstract] [Full Text] [Related]
16. Strategies for CT tissue segmentation for Monte Carlo calculations in nuclear medicine dosimetry.
Braad PE; Andersen T; Hansen SB; Høilund-Carlsen PF
Med Phys; 2016 Dec; 43(12):6507. PubMed ID: 27908147
[TBL] [Abstract] [Full Text] [Related]
17. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
Roberts AW; Davids MS; Pagel JM; Kahl BS; Puvvada SD; Gerecitano JF; Kipps TJ; Anderson MA; Brown JR; Gressick L; Wong S; Dunbar M; Zhu M; Desai MB; Cerri E; Heitner Enschede S; Humerickhouse RA; Wierda WG; Seymour JF
N Engl J Med; 2016 Jan; 374(4):311-22. PubMed ID: 26639348
[TBL] [Abstract] [Full Text] [Related]
18. Combined Mandibular Guidance Therapy in the Management of a Hemimandibulectomy Patient.
Jamayet NB; Fard AY; Husein A; Ariffin Z; Alam MK
Int J Prosthodont; 2015; 28(6):624-6. PubMed ID: 26523724
[TBL] [Abstract] [Full Text] [Related]
19. Hypoxia-induced apoptosis is blocked by adrenomedullin via upregulation of Bcl-2 in human osteosarcoma cells.
Wu XY; Hao CP; Ling M; Guo CH; Ma W
Oncol Rep; 2015 Aug; 34(2):787-94. PubMed ID: 26035796
[TBL] [Abstract] [Full Text] [Related]
20. Intrathecal injection of CD133-positive enriched bone marrow progenitor cells in children with cerebral palsy: feasibility and safety.
Zali A; Arab L; Ashrafi F; Mardpour S; Niknejhadi M; Hedayati-Asl AA; Halimi-Asl A; Ommi D; Hosseini SE; Baharvand H; Aghdami N
Cytotherapy; 2015 Feb; 17(2):232-41. PubMed ID: 25593079
[TBL] [Abstract] [Full Text] [Related]
[Next]
